Losartan Potassium Tablet, Film Coated
Product Images NDC 70518-0718

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 70518-0718). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium 100mg 70518 0718 01

Losartan Potassium 100 mg film-coated tablet label from RemedyRepack Inc. The label includes quantity of 90 tablets, RX only designation, NDC number 70518-0718-01, manufacturer Aurobindo, India, and storage directions. A barcode and QR code are also visible.*

FDA Label Image

Losartan Potassium 100mg 70518 0718 02

Losartan Potassium 100 mg film-coated tablets packaging label showing quantity of 30 tablets. The label includes the NDC number 70518-0718-02, states RX only, and indicates repackaging by RemedyRepack Inc. Manufacturer is Aurobindo, India. Storage instructions and barcode are also visible.*

FDA Label Image

Remedy_label (Remedy Label)

Losartan Potassium 100 mg film-coated tablets packaging label displays a quantity of 30 tablets. The label includes the NDC number 70518-0718-00, repackager RemedyRepack Inc., and manufacturer Aurobindo, India. It provides storage instructions and cautions to keep out of reach of children.*

FDA Label Image

Losartan Fig1

A line graph comparing the percentage of patients reaching a primary endpoint over a 66-month study period for Atenolol and Losartan Potassium. The graph includes a note on adjusted risk reduction of 13% with a p-value of 0.021, indicating statistical significance.*

FDA Label Image

Losartan Fig2

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a study period of 66 months for Atenolol and Losartan Potassium. The graph shows adjusted risk reduction of 25% for Losartan Potassium with a p-value of 0.001.*

FDA Label Image

Figure 3 (Losartan Fig3)

A figure showing primary endpoint events within demographic subgroups comparing Losartan Potassium and Atenolol. Two forest plots display hazard ratios with confidence intervals for primary composite events and stroke (fatal/non-fatal), segmented by age, gender, race, ISH, diabetes, and history of CVD. The horizontal axis ranges from 0.3 to 3, indicating relative favoring of Losartan or Atenolol.*

FDA Label Image

Figure-4 (Losartan Fig4)

A line graph showing the percentage of patients with events over 48 months, comparing Losartan Potassium (solid line) and placebo (dashed line). The graph indicates a 16.1% risk reduction with Losartan Potassium and includes a p-value of 0.022.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure diagram of Losartan Potassium showing the molecular arrangement of atoms and bonds in the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.